HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has received an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12-month consensus price objective of $6.00 for the company and are expecting that the company will post ($0.87) earnings per share for the current quarter, according to Zacks. Zacks has also given HTG Molecular Diagnostics an industry rank of 158 out of 265 based on the ratings given to its competitors.

A number of research analysts recently issued reports on the company. Rodman & Renshaw assumed coverage on HTG Molecular Diagnostics in a report on Monday, August 22nd. They issued a “buy” rating and a $5.00 price target for the company. Zacks Investment Research raised HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a report on Wednesday, July 13th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of HTG Molecular Diagnostics in a report on Thursday, October 13th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

HTG Molecular Diagnostics (NASDAQ:HTGM) traded down 4.56% during mid-day trading on Wednesday, hitting $2.51. 45,236 shares of the stock were exchanged. HTG Molecular Diagnostics has a 12-month low of $2.03 and a 12-month high of $6.03. The stock’s market capitalization is $17.70 million. The firm has a 50-day moving average price of $2.51 and a 200-day moving average price of $2.65.

HTG Molecular Diagnostics (NASDAQ:HTGM) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.95) by $0.03. Equities analysts predict that HTG Molecular Diagnostics will post ($3.58) earnings per share for the current fiscal year.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

5 Day Chart for NASDAQ:HTGM

Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related companies with's FREE daily email newsletter.